Publications

452 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Package advice on pegcetacoplan (Aspaveli®) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)

    The National Health Care Insititute has completed its assessment whether pegcetacoplan (Aspaveli®) can be included in the basic ...

    Report | 16-09-2022

  2. Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma

    The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...

    Report | 09-09-2022

  3. Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer

    The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...

    Report | 29-07-2022

  4. GVS advice testosterone undecanoate (Nebido®)

    The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

    Report | 21-07-2022

  5. Package advice risdiplam (Evrysdi®) for the treatment of 5q spinal muscular atrophy (SMA)

    The National Health Care Institute advises the Minister to include risdiplam (Evrysdi®) in the health insurance package for the ...

    Report | 15-07-2022

  6. GVS advice setmelanotide (Imcivree®)

    The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

    Report | 08-07-2022

  7. GVS advice metreleptin (Myalepta®)

    The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...

    Report | 08-07-2022

  8. GVS advice bempedoic acid (Nilemdo®) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia

    The National Health Care Institute has completed its assessment whether bempedoic acid is interchangeable with another medicinal ...

    Report | 05-07-2022

  9. GVS advice cannabidiol (Epidyolex®) as adjuvant treatment for 2 epileptic disorders

    The National Health Care Institute advises the Minister only to include cannabidiol (Epidyolex®) on List 1B of the Medicine ...

    Report | 04-07-2022

  10. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

    The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

    Report | 23-06-2022